PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease “KET-LID”
October 6, 2021
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease “KET-LID”
Awakn Life Sciences Announces Closing Of Acquisition Of Leading Ketamine-Assisted Psychotherapy Clinic In Norway Transaction
Delic Partnership With Paradigm Healthcare Of Georgia Brings Clinically Relevant Toxicology Testing To Ketamine Treatment
Awakn Life Sciences to Acquire Leading Ketamine-assisted Psychotherapy Clinic in Norway Launches Nordics Regional Expansion Dr.
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression NEW YORK
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 10 clinical sites
This West Philly Doctor Says Psychedelic-Assisted Therapy Could Change Your Life Psychedelic therapy clinics continue
Minnesota Psychedelic Therapy Clinic, Institute for Integrative Therapies, Begins Offering Psychedelic Therapy in a Group
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral